WhiteOak Capital Pharma and Healthcare Fund
WhiteOak Capital Pharma and Healthcare Fund portfolio holdings, Oct 2026: 52 stocks, ₹874 cr in listed equity, from WhiteOak Capital Mutual Fund's monthly disclosure; changes by share count against Sep 2026.
Fund managers: Ramesh Mantri; Piyush Baranwal; Dheeresh Pathak; Ashish Agrawal; Trupti Agrawal
Benchmark: BSE Healthcare TRI · Riskometer: Very High · SEBI category, as filed: Sectoral Fund · Allotted 6 Feb 2024
Source: AMFI scheme summary document
WhiteOak Capital Pharma and Healthcare Fund - Direct Plan - Growth Option
Source: AMFI
The scheme's yearly running cost as a % of its assets, taken out of the NAV a little each day. A regular plan costs more: it pays a distributor's commission.
Category median: direct 1.06 %, regular 2.50 % (20 schemes) · Regular costs ₹1,650 more a year per ₹1 lakh
Of this, the base expense ratio, the part SEBI caps: direct 0.51 %, regular 1.91 %. The rest is brokerage, transaction costs and statutory levies such as GST and STT, as AMFI's file lists them.
A year, as of 20 Nov 2026. Source: AMFI · Glossary: TER
52 stocks, Oct 2026.
As the AMC's file prints % of NAV. The top 10 stocks together: 44.6%.
This month: Oct 2026
compared with Sep 2026 · by share countMoves, Oct 2026
How many stocks the scheme bought into, added to, cut or sold out of this month, by share count, so a price move alone never counts.
- New3
- Added23
- Trimmed12
- Exited1
Asset mix, Oct 2026
How much of the fund sits in listed shares; the rest is foreign shares, debt, money market, cash and other assets.
- Listed equity90.6%
- Rest, not itemised9.4%
Rest = foreign shares, debt, money market, cash, REIT/InvIT units and other assets.
Sectors and top 10, Oct 2026
Sector mix, Oct 2026
How the scheme's equity is spread across sectors at month end.
- 95.0%
- 3.1%
- 1.9%
AMFI's 22 sectors; one sector per stock, from the fund houses' industry labels.
Large, mid and small cap, Oct 2026
How the scheme's equity splits across large, mid and small companies, on AMFI's list.
- Small Cap39.7%
- Large Cap30.1%
- Mid Cap26.9%
- Not in AMFI's list3.3%
AMFI's list of Jun 2026.
Top 10 holdings
Its ten largest stocks, each as a share of the fund.
- 8.87%
- 6.68%
- 5.87%
- 5.59%
- 3.73%
- 3.10%
- 3.02%
- 2.91%
- 2.50%
- 2.30%
As the AMC's file prints % of NAV.
Sector weight change
Each sector's share of the fund now less a month before. It moves with prices as well as trades.
- +0.2 pts
- −0.1 pts
- −0.1 pts
Largest moves first, up to 10.
| Stock | Change | Shares before | Shares now | Difference | Change % | Value of change | Value now |
|---|---|---|---|---|---|---|---|
| PARASHLTH | New | — | 1.38 lakh | +1.38 lakh | — | +₹10.2 cr | ₹10.2 cr |
| SMT | New | — | 1.49 lakh | +1.49 lakh | — | +₹6.9 cr | ₹6.9 cr |
| SYMBIOTEC | New | — | 14,256 | +14,256 | — | +₹1.8 cr | ₹1.8 cr |
| DIVISLAB | Added | 83,411 | 87,434 | +4,023 | +4.8% | +₹3.9 cr | ₹85.5 cr |
| TORNTPHARM | Added | 1.21 lakh | 1.23 lakh | +1,957 | +1.6% | +₹0.90 cr | ₹56.6 cr |
| LAURUSLABS | Added | 1.83 lakh | 2.24 lakh | +40,946 | +22.4% | +₹9.8 cr | ₹53.9 cr |
| ZYDUSLIFE | Added | 2.24 lakh | 2.40 lakh | +15,969 | +7.1% | +₹2.0 cr | ₹29.9 cr |
| IPCALAB | Added | 1.38 lakh | 1.46 lakh | +7,191 | +5.2% | +₹1.4 cr | ₹28.0 cr |
| MANKIND | Added | 44,418 | 96,668 | +52,250 | +117.6% | +₹13.0 cr | ₹24.1 cr |
| AUROPHARMA | Added | 1.16 lakh | 1.27 lakh | +10,906 | +9.4% | +₹1.8 cr | ₹21.3 cr |
| ACUTAAS | Added | 41,072 | 51,522 | +10,450 | +25.4% | +₹4.2 cr | ₹20.6 cr |
| AJANTPHARM | Added | 51,455 | 56,786 | +5,331 | +10.4% | +₹1.9 cr | ₹19.9 cr |
| KIMS | Added | 2.29 lakh | 2.81 lakh | +52,148 | +22.7% | +₹3.7 cr | ₹19.7 cr |
| MEDANTA | Added | 1.23 lakh | 1.44 lakh | +20,506 | +16.6% | +₹2.6 cr | ₹18.3 cr |
| NH | Added | 83,394 | 1.05 lakh | +21,293 | +25.5% | +₹3.7 cr | ₹18.0 cr |
| PPLPHARMA | Added | 4.75 lakh | 7.16 lakh | +2.41 lakh | +50.7% | +₹5.8 cr | ₹17.1 cr |
| VIJAYA | Added | 1.00 lakh | 1.13 lakh | +12,511 | +12.5% | +₹1.8 cr | ₹16.3 cr |
| PGHL | Added | 19,571 | 21,356 | +1,785 | +9.1% | +₹1.0 cr | ₹12.1 cr |
| AARTIPHARM | Added | 1.17 lakh | 1.17 lakh | +280 | +0.2% | +₹0.02 cr | ₹10.2 cr |
| AETHER | Added | 57,178 | 61,523 | +4,345 | +7.6% | +₹0.70 cr | ₹9.9 cr |
| INNOVACAP | Added | 50,655 | 70,924 | +20,269 | +40.0% | +₹2.1 cr | ₹7.3 cr |
| SUDEEPPHRM | Added | 35,099 | 64,838 | +29,739 | +84.7% | +₹3.2 cr | ₹6.9 cr |
| SENORES | Added | 53,704 | 60,375 | +6,671 | +12.4% | +₹0.76 cr | ₹6.8 cr |
| BIOCON | Added | 1.05 lakh | 1.58 lakh | +52,703 | +50.0% | +₹1.9 cr | ₹5.6 cr |
| EVONILE | Added | 11,712 | 25,730 | +14,018 | +119.7% | +₹2.4 cr | ₹4.4 cr |
| LAXMIDENTL | Added | 1.11 lakh | 1.55 lakh | +43,785 | +39.5% | +₹0.78 cr | ₹2.7 cr |
| SAILIFE | Trimmed | 1.99 lakh | 1.87 lakh | −12,530 | −6.3% | −₹2.0 cr | ₹29.1 cr |
| CIPLA | Trimmed | 2.53 lakh | 1.49 lakh | −1.04 lakh | −41.0% | −₹14.3 cr | ₹20.6 cr |
| LALPATHLAB | Trimmed | 1.10 lakh | 99,762 | −9,742 | −8.9% | −₹1.9 cr | ₹19.0 cr |
| NEULANDLAB | Trimmed | 11,278 | 9,443 | −1,835 | −16.3% | −₹3.6 cr | ₹18.6 cr |
| SHAILY | Trimmed | 55,537 | 52,452 | −3,085 | −5.6% | −₹0.98 cr | ₹16.6 cr |
| NAVINFLUOR | Trimmed | 15,874 | 15,870 | −4 | −0.0% | −₹0.00 cr | ₹13.8 cr |
| MAXHEALTH | Trimmed | 1.84 lakh | 1.42 lakh | −42,108 | −22.9% | −₹3.6 cr | ₹12.2 cr |
| ANTHEM | Trimmed | 1.70 lakh | 1.42 lakh | −27,103 | −16.0% | −₹2.2 cr | ₹11.8 cr |
| FORTIS | Trimmed | 1.64 lakh | 1.34 lakh | −30,035 | −18.3% | −₹2.3 cr | ₹10.3 cr |
| THYROCARE | Trimmed | 3.95 lakh | 2.14 lakh | −1.80 lakh | −45.7% | −₹8.2 cr | ₹9.8 cr |
| MOLBIO | Trimmed | 81,504 | 40,284 | −41,220 | −50.6% | −₹5.3 cr | ₹5.1 cr |
| ORCHPHARMA | Trimmed | 37,747 | 27,754 | −9,993 | −26.5% | −₹0.84 cr | ₹2.3 cr |
| RAINBOW | Exited | 80,848 | — | −80,848 | — | −₹10.6 cr | ₹10.6 cr |
Value of change = the difference in shares × this month's price in the AMC's file. Value now = the whole holding's market value in that file (an exit: last month's).
Show all 52 stocksShow the first 15
Equity rows as disclosed, Oct 2026. Source: WhiteOak Capital Mutual Fund monthly portfolio. Report a wrong number
Large, mid and small caps, % of net assets, last 12 months
AMFI list in force each month
| Month | Large | Mid | Small | Not in AMFI's list | AMFI list |
|---|---|---|---|---|---|
| Oct 2026 | 27.3% | 24.4% | 36.0% | 2.9% | Jun 2026 |
| Sep 2026 | 29.2% | 21.7% | 38.2% | 1.7% | Jun 2026 |
| Aug 2026 | 30.6% | 21.6% | 39.3% | 2.1% | Jun 2026 |
| Jul 2026 | 28.7% | 23.0% | 41.8% | 1.0% | Jun 2026 |
| Jun 2026 | 22.5% | 18.1% | 51.5% | 0.0% | Dec 2025 |
| May 2026 | 21.2% | 18.3% | 52.3% | 0.0% | Dec 2025 |
| Apr 2026 | 21.9% | 23.3% | 47.7% | 0.0% | Dec 2025 |
| Mar 2026 | 26.4% | 24.6% | 42.4% | 0.0% | Dec 2025 |
| Feb 2026 | 27.8% | 22.0% | 44.0% | 0.0% | Dec 2025 |
| Jan 2026 | 26.4% | 23.4% | 45.5% | 0.0% | Dec 2025 |
| Dec 2025 | 33.3% | 19.3% | 38.6% | 2.5% | Jun 2025 |
| Nov 2025 | 28.5% | 19.0% | 40.3% | 2.1% | Jun 2025 |
Equity holdings' % of net assets each month, by AMFI's cap list in force that month.
Portfolio turnover, from holdings
equity only · month-end snapshots
| Month | Bought | Sold | Turnover |
|---|---|---|---|
| Oct 2026 | ₹88.1 cr | ₹55.1 cr | 6.4% |
| Sep 2026 | ₹58.6 cr | ₹34.5 cr | 4.1% |
| Aug 2026 | ₹93.6 cr | ₹52.0 cr | 6.4% |
| Jul 2026 | ₹168 cr | ₹94.9 cr | 13.0% |
| Jun 2026 | ₹63.6 cr | ₹32.3 cr | 5.0% |
| May 2026 | ₹85.8 cr | ₹68.4 cr | 11.7% |
| Apr 2026 | ₹59.9 cr | ₹55.7 cr | 10.3% |
| Mar 2026 | ₹67.4 cr | ₹28.5 cr | 5.6% |
| Feb 2026 | ₹52.9 cr | ₹53.2 cr | 10.9% |
| Jan 2026 | ₹55.7 cr | ₹39.9 cr | 8.5% |
| Dec 2025 | ₹62.8 cr | ₹22.9 cr | 4.9% |
| Nov 2025 | ₹66.9 cr | ₹55.4 cr | 12.5% |
The lower of bought and sold over the average equity value, from month-end holdings; it can differ from the fund house's own figure.
| Period | Direct plan | Regular plan | Benchmark, as published by AMFI BSE Healthcare TRI |
|---|---|---|---|
| 1 year | +26.20 % | +24.05 % | +19.11 % |
| Since launch | +24.34 % | +22.20 % | +17.05 % |
Past performance may not be sustained in future.
As AMFI's fund performance report prints them for "WhiteOak Capital Pharma and Healthcare Fund"; this site computes no benchmark figure of its own.
How it is computed: NAV to NAV
WhiteOak Capital Pharma and Healthcare Fund - Direct Plan - Growth Option: these run to the newest NAV stored (20 Nov 2026) and are computed here from AMFI's NAV files; AMFI's figures above run to 19 Nov 2026, so the two differ by the days in between.
| Period | Return | From | To |
|---|---|---|---|
| 1 year | +26.82 % in total | 20 Nov 2025 · NAV ₹14.5500 | 20 Nov 2026 · NAV ₹18.4520 |
| Since first NAV | +24.27 % a year, compounded | 7 Feb 2024 · NAV ₹10.0730 | 20 Nov 2026 · NAV ₹18.4520 |
Source: AMFI NAV files (plan code 152349). How to read Report a wrong number
Not enough NAV history stored yet for rolling returns and a monthly SIP.
IDCW (dividend) history
0 declarations · as of 3 Nov 2026 · Source: AMFI
IDCW (formerly "dividend") declared per unit of each IDCW plan, as AMFI lists it.
Calendar-year returns, WhiteOak Capital Pharma and Healthcare Fund - Direct Plan - Growth Option
NAV to NAV · Source: AMFI
| Year | Return | From | To |
|---|---|---|---|
| 2025 | +1.84 % | 31 Dec 2024 · NAV ₹13.9420 | 31 Dec 2025 · NAV ₹14.1990 |
Past performance may not be sustained in future.
Change in the plan's NAV over each calendar year, last NAV to last NAV. Source: AMFI NAV files. How to read
Embed this card
Copy this into any web page. The image carries its source, date and a link back; it is redrawn each night.
- SBI Healthcare Opportunities Fund57.7% overlap29 in common
- Kotak Healthcare Fund53.8% overlap23 in common
- Mirae Asset Healthcare Fund53.3% overlap20 in common
- Baroda BNP Paribas Health and Wellness Fund51.9% overlap20 in common
- Bajaj Finserv Healthcare Fund51.9% overlap21 in common
Overlap is the sum, over stocks both hold, of the smaller of the two weights. A measured likeness, not a suggestion to switch.
- 20 Nov 2026 · TER change: WhiteOak Capital Pharma and Healthcare Fund: AMFI TER file of 20 Nov 2026: direct plan 1.04% (was 1.05%); regular plan 2.69% (was 2.70%); previous file 18 Nov 2026
- 17 Nov 2026 · TER change: WhiteOak Capital Pharma and Healthcare Fund: AMFI TER file of 17 Nov 2026: direct plan 1.05% (was 1.04%); regular plan 2.70% (was 2.69%); previous file 15 Nov 2026
- 13 Nov 2026 · TER change: WhiteOak Capital Pharma and Healthcare Fund: AMFI TER file of 13 Nov 2026: direct plan 1.04% (was 1.05%); regular plan 2.69% (was 2.70%); previous file 11 Nov 2026
- 8 Nov 2026 · TER change: WhiteOak Capital Pharma and Healthcare Fund: AMFI TER file of 8 Nov 2026: regular plan 2.70% (was 2.71%); previous file 6 Nov 2026
- 6 Nov 2026 · TER change: WhiteOak Capital Pharma and Healthcare Fund: AMFI TER file of 6 Nov 2026: direct plan 1.05% (was 1.06%); previous file 5 Nov 2026
From AMFI's own files (scheme summary documents, NAV history, TER), as they stood on the day shown.
Questions about WhiteOak Capital Pharma and Healthcare Fund
from the figures on this pageWhat are the top holdings of WhiteOak Capital Pharma and Healthcare Fund?
At Oct 2026 end, WhiteOak Capital Pharma and Healthcare Fund held 52 stocks (90.6% of the fund in equity). Largest: Divi's Laboratories 8.87%, Sun Pharmaceutical Industries 6.68%, Torrent Pharmaceuticals 5.87%, Laurus Labs 5.59%, Apollo Hospitals Enterprise 3.73%; the top 10 make up 44.6%. Funds holding Divi's Laboratories · Funds holding Sun Pharmaceutical Industries · Funds holding Torrent Pharmaceuticals
What portfolio changes did WhiteOak Capital Pharma and Healthcare Fund make in Oct 2026?
Compared with Sep 2026, by share count: 3 new, 23 added, 12 trimmed, 1 exited. Largest by value: Paras Healthcare (new), Sahajanand Medical Technologies (new), Symbiotec Pharmalab (new), Divi's Laboratories (added).
Who manages WhiteOak Capital Pharma and Healthcare Fund?
AMFI's scheme summary document names Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal for WhiteOak Capital Pharma and Healthcare Fund (WhiteOak Capital Mutual Fund). Ramesh Mantri, fund manager portfolio · Piyush Baranwal, fund manager portfolio · Dheeresh Pathak, fund manager portfolio
All schemes of WhiteOak Capital Mutual Fund →
Mutual fund investments are subject to market risks; read all scheme related documents carefully.